Discovery of AZD4625, a Covalent Allosteric Inhibitor of the Mutant GTPase KRAS^G12C

Abstract

KRAS is an archetypal high-value intractable oncology drug target. The glycine to cysteine mutation at codon 12 represents an Achilles heel that has now rendered this important GTPase druggable. Herein, we report our structure-based drug design approach that led to the identification of <b>21</b>, AZD4625, a clinical development candidate for the treatment of KRAS^G12C positive tumors. Highlights include a quinazoline tethering strategy to lock out a bio-relevant binding conformation and an optimization strategy focused on the reduction of extrahepatic clearance mechanisms seen in preclinical species. Crystallographic analysis was also key in helping to rationalize unusual structure-activity relationship in terms of ring size and enantio-preference. AZD4625 is a highly potent and selective inhibitor of KRAS^G12C with an anticipated low clearance and high oral bioavailability profile in humans.